836 followers
RT @CCR_AACR: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial…
2,553 followers
RT @CCR_AACR: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial…
3,118 followers
RT @CCR_AACR: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial…
1,231 followers
RT @CCR_AACR: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial…
40 followers
RT @CCR_AACR: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial…
1,053 followers
RT @CCR_AACR: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial…
1,053 followers
RT @EANOassociation: Favorable safety profile and 18% objective response rate in non-enhancing IDH-mutated #glioma with first-in-class IDH1…
373 followers
RT @EANOassociation: Favorable safety profile and 18% objective response rate in non-enhancing IDH-mutated #glioma with first-in-class IDH1…
1,365 followers
RT @EANOassociation: Favorable safety profile and 18% objective response rate in non-enhancing IDH-mutated #glioma with first-in-class IDH1…
1,573 followers
RT @EANOassociation: Favorable safety profile and 18% objective response rate in non-enhancing IDH-mutated #glioma with first-in-class IDH1…
314 followers
102 followers
RT @CCR_AACR: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial…
801 followers
RT @EANOassociation: Favorable safety profile and 18% objective response rate in non-enhancing IDH-mutated #glioma with first-in-class IDH1…
3,769 followers
6,779 followers
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. https://t.co/aAFsf5D3Yk. #Targets21 https://t.co/CIvDS7UAqJ
348 followers
BRAIN: the IDH1/2 inhibitor vorasidenib was well tolerated and showed some efficacy in a phase 1 study of IDH-mutant low grade glioma. https://t.co/3Q5qfdf3Xt
485 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
6,779 followers
Phase 1 Study: Vorasidenib in recurrent or progressive glioma. https://t.co/k1D0toAzlT https://t.co/Ozt1LMkya1
254 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
267 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
11 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
557 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
213 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
7,571 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
28,099 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
4,050 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
5,102 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
452 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
2,485 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
1,615 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
2,236 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
791 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
6,330 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
3,077 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
17,651 followers
RT @JavleMilind: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Tr…
1,459 followers
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial https://t.co/Pn99ZXbUgQ Impressive PFS median 36.8 mos. Potential implication for IDH1/2 cholangiocarcinoma @curecc @CcaEns @CCA_A
369 followers
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial https://t.co/H4s4SBKdhT
5,289 followers
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial https://t.co/9swSaSquCh #gedefo #feedly
7,428 followers
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial https://t.co/USWcVLABM1
192 followers
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive #Glioma. #LGG https://t.co/ALSSObu6wy
7,428 followers
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial https://t.co/4lhZglwLPS #BrainTumorThursday
4,240 followers
In a recent @AACR clinical trial, Dr. Timothy Cloughesy & other researchers found that Vorasidenib was well tolerated and showed preliminary antitumor activity in patients with lower-grade gliomas. https://t.co/ZkQbby9jZ3 https://t.co/ygkZiQYsgs
6,779 followers
#Vorasidenib, a first-in-class brain-penetrant inhibitor of mutant IDH1/2 (mIDH1/2), showed a favorable safety profile and preliminary clinical activity in recurrent or progressive mIDH1/2 #glioma. @DrMartaPPrado https://t.co/hqIJqZotlZ https://t.co/l7Jddo
6,779 followers
RT @JBrosnanCashman: Dr. Ingo Mellinghoff is presenting data on the mIDH1/2 inhibitor vorasidenib in patients with low-grade #glioma at #AS…
148 followers
Dr. Ingo Mellinghoff is presenting data on the mIDH1/2 inhibitor vorasidenib in patients with low-grade #glioma at #ASCO21. For more, read this related #clinicaltrial from Dr. Mellinghoff, now online in @CCR_AACR. @sloan_kettering https://t.co/gdNRJllWw
7,428 followers
Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; Results of a first-in-human Phase I trial https://t.co/llZs8VWZDi